Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $67M | $14M | $9M | $-3M | 24.5% | 23.7% | 322.1% |
| 2024 | $54M | $4M | $2M | $5M | 6.9% | 16.8% | -69.9% |
| 2023 | $46M | $11M | $7M | $4M | 22.4% | 9.6% | 54.7% |
| 2022 | $42M | $7M | $5M | $-3M | 18.0% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 66.59 |
| Operating Revenue | 68.09 |
| Cost Of Revenue | 47.08 |
| Gross Profit | 19.51 |
| Operating Expense | 8.82 |
| Research And Development | 3.64 |
| Selling General And Administration | 5.18 |
| Total Expenses | 55.90 |
| Operating Income | 10.69 |
| Total Operating Income As Reported | 10.69 |
| EBITDA | 14.13 |
| Normalized EBITDA | 12.01 |
| EBIT | 12.89 |
| Interest Income | 0.08 |
| Interest Expense | 0.83 |
| Net Interest Income | -0.75 |
| Other Income Expense | 2.12 |
| Interest Income Non Operating | 0.08 |
| Interest Expense Non Operating | 0.83 |
| Net Non Operating Interest Income Expense | -0.75 |
| Pretax Income | 12.06 |
| Tax Provision | 3.08 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0.54 |
| Net Income Continuous Operations | 8.98 |
| Net Income From Continuing And Discontinued Operation | 8.98 |
| Net Income From Continuing Operation Net Minority Interest | 8.98 |
| Net Income | 8.98 |
| Net Income Common Stockholders | 8.98 |
| Net Income Including Noncontrolling Interests | 8.98 |
| Normalized Income | 7.40 |
| Diluted NI Availto Com Stockholders | 8.98 |
| Basic Average Shares | 3.29 |
| Diluted Average Shares | 3.36 |
| Reconciled Depreciation | 1.24 |
| Reconciled Cost Of Revenue | 47.08 |
| Total Unusual Items | 2.12 |
| Total Unusual Items Excluding Goodwill | 2.12 |
| Special Income Charges | - |
| Gain On Sale Of Security | 2.12 |
| General And Administrative Expense | 4.84 |
| Other Gand A | 4.84 |
| Gain On Sale Of Ppe | - |
| Selling And Marketing Expense | 0.34 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Pro-Dex, Inc.this co. | PDEX | $214M | 23.83 | 5.84 | 24.5% | 16.29 |
| Fulcrum Therapeutics, Inc. | FULC | $225M | - | 0.64 | -21.5% | - |
| Foghorn Therapeutics Inc. | FHTX | $220M | -2.96 | -2.02 | 68.5% | -2.28 |
| Inhibikase Therapeutics, Inc. | IKT | $219M | -4.54 | 1.27 | -27.9% | -1.50 |
| Voyager Therapeutics, Inc. | VYGR | $219M |
| - |
| - |
| - |
| - |
| -1.83 |
| 1.12 |
| -61.1% |
| -1.49 |
| Utah Medical Products, Inc. | UTMD | $216M | 19.17 | 1.82 | 9.5% | 9.09 |
| Keros Therapeutics, Inc. | KROS | $213M | 2.45 | 0.70 | 28.7% | -0.83 |
| RxSight, Inc. | RXST | $211M | -5.42 | 0.77 | -14.1% | -5.68 |
| Atrium Therapeutics, Inc. | RNA | $210M | -2.74 | 1.02 | -37.0% | 0.73 |
| Peer Median | - | -2.74 | 0.89 | -17.8% | -1.49 | |